ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2021
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2023Pooled it
- Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Pooled it
- A retrospective cohort study on the differential overall survival rates between surgical intervention and chemotherapy in stage IV pancreatic cancer patients.Gland surgery · 2025Article
- Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation.Cancers · 2025Review
- Improving outcomes of patients with pancreatic cancer.Nature reviews. Clinical oncology · 2025Review
- Kappa opioid receptor internalisation-induced p38 nuclear translocation suppresses glioma progression.British journal of anaesthesia · 2025Article
- Complementary strategies in pancreatic cancer precision medicine: therapeutic prediction and immune modulation.Frontiers in oncology · 2025Review
- RELATIONSHIP OF IMMUNOHISTOCHEMICAL EXPRESSION OF CD86/CD163 POSITIVE INTRATUMORAL MACROPHAGES WITH PROGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA.Acta clinica Croatica · 2024Article
- Article
- Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.Cancers · 2024Review
- Analytical Validation of Loss of Heterozygosity and Mutation Detection in Pancreatic Fine-Needle Aspirates by Capillary Electrophoresis and Sanger Sequencing.Diagnostics (Basel, Switzerland) · 2024Article
- TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth.Antibodies (Basel, Switzerland) · 2024Article
- Identification of key biomarkers and associated pathways of pancreatic cancer using integrated transcriptomic and gene network analysis.Saudi journal of biological sciences · 2023Article
- A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.Current oncology (Toronto, Ont.) · 2023Review
- RareWorld journal of clinical cases · 2023Article
- Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.Cancers · 2023Review
- Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling.Neoplasia (New York, N.Y.) · 2023Article
- Phage-based peptides for pancreatic cancer diagnosis and treatment: alternative approach.Frontiers in microbiology · 2023Review
- Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.Therapeutic advances in medical oncology · 2023Review
- Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
Abstract
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of 'all-comer' treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.